Gdc 0980

PC9 cells were from Kyushu University, Japan. EVSA-T and MKN-45 cells were from DSMZ. All other cell lines were from American Type Culture Collection. All cell lines were banked at the Genentech cell line core facility that routinely performs single nucleotide polymorphism (SNP) and short tandem repeats (STR) analysis to confirm cell line identity and detect possible mycoplasma contamination. PC9 cells were cultured in RPMI medium (Gibco) containing 4.5 g l⁻¹ of D-glucose and supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 U ml⁻¹ of penicillin and streptomycin. All other cell lines were maintained in RPMI medium (Gibco) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 U ml⁻¹ of penicillin and streptomycin. Lapatinib was from LC Laboratories, cinnamycin was from Sigma, AACOCF3 was from Santa Cruz Biotechnology, paclitaxel was from US Biologicals, carboplatin was from Selleckchem, AZ628 was from Tocris Bioscience, Bisindolylmaleimide I, XI and XI were from Cayman Chemicals, PKC-20-28 was from EMD Millipore, phorbol-12-myristate13-acetate was from VWR Scientific, and erlotinib and GDC-0980 were synthesized at Genentech.

Recombinant human HGF was purchased from R&D Systems (Minneapolis, MN, USA) GDC-0980 was kind gift from Genentech (San Francisco, CA, USA), crizotinib and BKM120 were purchased from Selleck Chemicals (Houston, TX, USA). Stock solutions were prepared in DMSO and stored at −20 °C.